Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KALA KALA BIO	$4.04 -4.7%	$3.78	$2.92 ▼ $11.20	$26.06M	-1.98	95,793 shs	23,275 shs
SYBX Synlogic	$1.26 +3.8%	$1.15	$0.90 ▼ $1.88	$14.74M	0.51	17,444 shs	4,615 shs
UBX UNITY Biotechnology	$0.81 +1.9%	$0.85	$0.66 ▼ $3.10	$13.85M	1.06	164,385 shs	80,080 shs
VLON Vallon Pharmaceuticals	$1.32 -5.7%	$0.67	$0.21 ▼ $12.92	$17.80M	-1.14	5.78 million shs	112,557 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KALA KALA BIO	0.00%	-6.05%	0.00%	-41.11%	-25.19%
SYBX Synlogic	0.00%	+2.02%	+11.50%	-2.40%	-15.44%
UBX UNITY Biotechnology	0.00%	+0.88%	+3.34%	-38.08%	-42.50%
VLON Vallon Pharmaceuticals	0.00%	+1.54%	+5.60%	-84.04%	-50.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KALA KALA BIO	2.4384 of 5 stars	3.5	1.0	0.0	4.4	0.0	0.8	0.6
SYBX Synlogic	0.8795 of 5 stars	0.0	3.0	0.0	0.0	2.3	1.7	0.6
UBX UNITY Biotechnology	3.3377 of 5 stars	3.3	2.0	0.0	4.7	0.0	0.8	0.6
VLON Vallon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KALA KALA BIO	3.00	Buy	$13.50	234.16% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A
UBX UNITY Biotechnology	2.50	Moderate Buy	$3.75	365.84% Upside
VLON Vallon Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest UBX, KALA, SYBX, and VLON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/27/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$4.00 ➝ $2.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/16/2025	UBX UNITY Biotechnology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$6.00 ➝ $1.00
4/23/2025	UBX UNITY Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/23/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/4/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/25/2025	UBX UNITY Biotechnology	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
3/24/2025	UBX UNITY Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KALA KALA BIO	$3.89M	6.70	N/A	N/A	$2.02 per share	2.00
SYBX Synlogic	$10K	1,474.20	N/A	N/A	$1.09 per share	1.16
UBX UNITY Biotechnology	$240K	57.73	N/A	N/A	$0.39 per share	2.06
VLON Vallon Pharmaceuticals	$100K	177.96	N/A	N/A	$0.18 per share	7.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	10.91%	7.47%	6/24/2025 (Estimated)
UBX UNITY Biotechnology	-$25.99M	-$1.62	N/A	N/A	N/A	N/A	-246.82%	-58.81%	7/22/2025 (Estimated)
VLON Vallon Pharmaceuticals	-$7.02M	-$0.78	N/A	∞	N/A	N/A	-230.48%	-124.89%	N/A

Latest UBX, KALA, SYBX, and VLON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/24/2025	Q1 2025	SYBX Synlogic	-$0.15	$0.0256	+$0.1756	N/A	N/A	N/A
4/22/2025	Q1 2025	UBX UNITY Biotechnology	-$0.43	-$0.43	N/A	-$0.43	N/A	N/A
3/28/2025	Q4 2024	KALA KALA BIO	-$2.28	-$1.74	+$0.54	-$1.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A
UBX UNITY Biotechnology	N/A	N/A	N/A	N/A	N/A
VLON Vallon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KALA KALA BIO	3.19	1.99	1.99
SYBX Synlogic	N/A	3.68	3.68
UBX UNITY Biotechnology	N/A	1.95	1.95
VLON Vallon Pharmaceuticals	N/A	2.29	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KALA KALA BIO	24.61%
SYBX Synlogic	63.40%
UBX UNITY Biotechnology	29.49%
VLON Vallon Pharmaceuticals	8.74%

Insider Ownership

Company	Insider Ownership
KALA KALA BIO	8.32%
SYBX Synlogic	3.02%
UBX UNITY Biotechnology	5.80%
VLON Vallon Pharmaceuticals	37.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
SYBX Synlogic	80	11.70 million	11.34 million	Optionable
UBX UNITY Biotechnology	60	17.21 million	16.21 million	Optionable
VLON Vallon Pharmaceuticals	3	13.48 million	8.45 million	Not Optionable

UBX, KALA, SYBX, and VLON Headlines

Recent News About These Companies

Questcor Pharmaceuticals,

July 21, 2023 | forbes.com

Vallon Pharmaceuticals' shareholders approve reverse merger with California company

April 20, 2023 | bizjournals.com

Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split

April 20, 2023 | finance.yahoo.com

Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023

April 12, 2023 | finance.yahoo.com

Lab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for merger

April 7, 2023 | bizjournals.com

Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET

April 4, 2023 | finance.yahoo.com

Vallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results

February 24, 2023 | finanznachrichten.de

Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results

February 24, 2023 | finance.yahoo.com

Is Vallon Pharmaceuticals Inc (VLON) recent surge justified

February 14, 2023 | benzinga.com

Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event

January 11, 2023 | finance.yahoo.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLON

December 27, 2022 | benzinga.com

Vallon rockets as it announces merger with GRI Bio

December 15, 2022 | thepharmaletter.com

Say goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on Nasdaq

December 14, 2022 | endpts.com

Vallon Pharmaceuticals to merge with California biotech firm in 'best path forward'

December 14, 2022 | bizjournals.com

What's Going On With Vallon Pharmaceuticals Stock Today?

December 14, 2022 | msn.com

Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket

December 14, 2022 | benzinga.com

Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators

December 13, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 3, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 28, 2022 | finance.yahoo.com

Vallon Pharmaceuticals, Inc. (VLON)

July 20, 2022 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UBX, KALA, SYBX, and VLON Company Descriptions

KALA BIO NASDAQ:KALA

$4.04 -0.20 (-4.72%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.12 +0.08 (+1.98%)

As of 06/20/2025 05:01 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Synlogic NASDAQ:SYBX

$1.26 +0.05 (+3.79%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.00 (+0.32%)

As of 06/20/2025 04:01 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

UNITY Biotechnology NASDAQ:UBX

$0.80 +0.01 (+1.87%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+0.62%)

As of 06/20/2025 07:45 PM Eastern

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Vallon Pharmaceuticals NASDAQ:VLON

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time